reslizumab asthma
Selected indexed studies
- Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. (Allergy, 2020) [PMID:32034960]
- Real-world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: A systematic review and meta-analysis. (Clin Exp Allergy, 2022) [PMID:35174566]
- Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. (Lancet Respir Med, 2015) [PMID:25736990]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. (2020) pubmed
- Real-world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: A systematic review and meta-analysis. (2022) pubmed
- Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. (2015) pubmed
- Reslizumab in Eosinophilic Asthma: A Review. (2017) pubmed
- Type 2 inflammation in asthma and other airway diseases. (2022) pubmed
- Pharmacokinetic/pharmacodynamic profile of reslizumab in asthma. (2018) pubmed
- Update on reslizumab for eosinophilic asthma. (2015) pubmed
- Asthma in adults: Principles of treatment. (2019) pubmed
- Choosing the Right Biologic for the Right Patient With Severe Asthma. (2025) pubmed
- Reslizumab and mepolizumab for moderate-to-severe poorly controlled asthma: an indirect comparison meta-analysis. (2019) pubmed